The radiosensitising properties of PI3K/AKT/mTOR inhibitors have also been demonstrated in soft tissue sarcoma, bladder transitional cell carcinoma, hepatocellular carcinoma, metastatic renal cell carcinoma Burkitt’s lymphoma (Table 4), SCC of the cervix (Table 2) and pancreatic cancer (Table 1). The gene discussed is MTOR; the disease is pancreatic neoplasm.